Figure 2. Survival outcomes of EC patients treated with ICI categorized by BMI.

Kaplan-Meier curves for (A) PFS and (B) OS in patients with EC treated with ICI and categorized by BMI (normal: BMI 18.5–24.9 kg/m² in blue; overweight: BMI 25–29.9 kg/m² in red; obese: BMI >30 kg/m² in green) (n = 524). Kaplan-Meier curves for (C) PFS and (D) OS in the subgroup of EC patients treated with the ICI pembrolizumab in combination with lenvatinib (n = 307). P values in the PFS and OS plots were calculated using a log-rank test. HRs and 95% CIs for overweight and obese patients were calculated using normal BMI as a reference.